Paget's carcinoma of the breast.

J. B. Davis,C. Bowie

1972-05-01

Abstract:

What problem does this paper attempt to address?

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

Yanzhong Wang,Jin Zeng,Weiping Wu,Shuduo Xie,Haitao Yu,Guoli Li,Tao Zhu,Fengying Li,Jie Lu,Gavin Y. Wang,Xinyou Xie,Jun Zhang

DOI: https://doi.org/10.1186/s13058-019-1150-z

2019-01-01

Breast Cancer Research

Abstract:Background Nicotinamide N -methyltransferase (NNMT) is overexpressed in various human tumors and involved in the development and progression of several carcinomas. In breast cancer, NNMT was found to be overexpressed in several cell lines. However, the clinical relevance of NNMT in breast cancer is not yet clear. Methods NNMT expression in breast carcinoma was examined by immunohistochemistry, and then, its relationship with patient clinicopathological characteristics was analyzed. The effects of NNMT on chemoresistance in breast cancer cells were assessed by cell viability, colony formation, and apoptosis assay. The NNMT, SIRT1, p53, and acetyl-p53 proteins, which are involved in NNMT-related chemoresistance, were examined by Western blotting. The SIRT1 mRNA was examined by real-time PCR, and its activity was measured by using the SIRT1 deacetylase fluorometric reagent kit. Results NNMT expression was significantly higher (53.9%) in breast carcinoma than in paracancerous tissues (10.0%) and breast hyperplasia (13.3%). A high level of NNMT expression correlated with poor survival and chemotherapy response in breast cancer patients who received chemotherapy. Ectopic overexpression of NNMT significantly inhibited the apoptotic cell death and suppression of colony formation induced by adriamycin and paclitaxel. Mechanistic studies revealed that NNMT overexpression increased SIRT1 expression and promoted its activity. Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer. Conclusions The results of this study demonstrate a novel correlation between the NNMT expression level and patient survival, suggesting that NNMT has the potential to become a new prognostic biomarker to predict the treatment outcomes of the clinical chemotherapy in breast cancer. Moreover, targeting NNMT or downstream SIRT1 may represent a new therapeutic approach to improve the efficacy of breast cancer chemotherapy.
S-adenosylmethionine Inhibits Non-Small Cell Lung Cancer and Enhances Chemosensitivity by Targeting the P62/NF-κB Axis and Regulating Autophagy and Oxidative Stress

Xuehang Jin,Lvjun Zhang,Chiqing Ying,Long Yu,Xuejing Guo,Kailing Pan,Dan Zhu,Hui Chen,Yan Lou,Yunqing Qiu

DOI: https://doi.org/10.21203/rs.3.rs-5412638/v1

2024-01-01

Abstract:Background Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. S-adenosylmethionine (SAM), a key metabolite in the methionine cycle, has indicated potential for cancer therapy and enhancing chemotherapy sensitivity. However, its effects on NSCLC remain undetermined. Methods Cell lines and mouse models were utilized to assess the anti-tumor efficacy of SAM. We constructed biotin-labeled SAM and truncated P62 expression plasmids for further immunocoprecipitation-mass spectrometry experiments. Results SAM inhibits NSCLC growth and enhances chemosensitivity both in vitro and in vivo. Mechanistic investigations revealed that SAM plays a significant regulatory role in autophagy and oxidative stress within NSCLC. Furthermore, we identified P62 as a critical target of SAM. Both in vitro and in vivo studies confirmed that P62 mediates SAM regulatory effects on NSCLC. Further study discovered that SAM inhibits the NF-κB signaling pathway by directly targeting the ZZ and TB domains of the P62 protein, thereby blocking autophagy and activating oxidative stress. Conclusions These findings highlight SAM as a novel inhibitor of the P62/NF-κB axis and suggest that SAM could be a potential therapeutic agent for NSCLC.
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.

Xinyou Xie,Huixing Liu,Yanzhong Wang,Yanwen Zhou,Haitao Yu,Guiling Li,Zhi Ruan,Fengying Li,Xiuhong Wang,Jun Zhang

DOI: https://doi.org/10.18632/oncotarget.9962

2016-01-01

Oncotarget

Abstract:Nicotinamide N-methyltransferase (NNMT), which converts nicotinamide to 1-methylnicotinamide (1-MNA), is overexpressed in a variety of human cancers and serves as a potential anti-cancer target. In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms. Our results show that down-regulation of NNMT in CRC HT-29 cells diminishes 5-FU resistance, while over expression of NNMT in SW480 cells enhances it. NNMT reduces reactive oxygen species (ROS) production induced by 5-FU by increasing 1-MNA in CRC cells. The reduction in ROS leads to inactivation of the ASK1-p38 mitogen-activated protein kinase (MAPK) pathway, which reduces 5-FU-induced apoptosis. In vivo, NNMT attenuates 5-FU-induced inhibition of CRC tumor growth in nude mice. These observations suggest that NNMT and the 1-MNA it produces inhibit the ASK1-p38 MAPK pathway, resulting in increased CRC cell resistance to 5-FU.
Nicotinamide N-methyltransferase Enhances the Capacity of Tumorigenesis Associated with the Promotion of Cell Cycle Progression in Human Colorectal Cancer Cells.

Xinyou Xie,Haitao Yu,Yanzhong Wang,Yanwen Zhou,Guiling Li,Zhi Ruan,Fengying Li,Xiuhong Wang,Huixing Liu,Jun Zhang

DOI: https://doi.org/10.1016/j.abb.2014.08.017

IF: 4.114

2014-01-01

Archives of Biochemistry and Biophysics

Abstract:Nicotinamide N-methyltransferase (NNMT), an enzyme involved in the biotransformation and detoxification of many drugs and xenobiotic compounds, has been found to be overexpressed in several malignancies, including colorectal cancer. However, the biological function of NNMT and the related mechanisms in colorectal cancer have not been elucidated. In the present study, we investigated the effects of NNMT on tumorigenesis by overexpressing NNMT in the human colorectal cancer cells line SW480 which lacks constitutive NNMT expression, and downregulating NNMT expression in HT-29 cells, which exhibit high endogenous expression of NNMT. We found that NNMT significantly accelerates cell proliferation, enhances colony formation in vitro and tumorigenicity in mice; it also inhibits apoptosis, promotes cell cycle progression, increases ATP and 1-methylnicotinamide level and decreases ROS level. We also showed that 1-methylnicotinamide accelerates cell growth, inhibits apoptosis, promotes cell cycle progression, attenuates ROS production and increases ATP level. Our results indicate that NNMT enhances the capacity of tumorigenesis associated with the inhibition of cell apoptosis and the promotion of cell cycle progression in human colorectal cancer cells and the 1-methylnicotinamide increased by NNMT mediates the cellular effects of NNMT in cells. NNMT may play a vital role in energy balance and ROS induction.
NSAID Indomethacin Enhanced Cytostatic Effect of Cis-Platinum of the Proliferation of Prostaglandin Producing and Non-Producing Cancers in Cell Line

M. Ogino,S. Okinaga,M. Kaibara,I. Ishiwata

DOI: https://doi.org/10.1007/978-1-4615-3874-5_60

1991-01-01

Abstract:Non-steroidal anti-inflammatory drug, INDOMETHACIN, a potent cyclooxygenase inhibitor, has been recently regarded as biological response modifier in that it inhibits the production of immunosuppressing prostaglandins, among which prostaglandin E2 has been shown to play a clear role in the regulation of lymphokine production and considered as being involved in the suppression of immune response system (1). Therefore, indomethacin has been thought to exert its anti-tumor effect through stimulating cellular immune function by inhibiting the formation of immunosuppressing prostaglandins (2). In the early 80’s, some papers have reported the anti-tumor effect of indomethacin by in vivo studies (3) (4). Furthermore, in the other works, indomethacin has been revealed to enhance the immunocompetence (5) (6). In this way, most of these documents attributed to the anti-tumor effect of indomethacin to the inhibition of increased formation of immunosuppressing prostaglandin E2 by the cancer per se and/or as a result of paraneoplastic manifestation. However, there have been a very few number of papers issued reporting direct cytostatic effect of indomethacin. In the present study, we obtained prostaglandin producing and non-producing cell lines of the uterine cervical cancer, then we assessed the changes in cell growth of the cancer when indomethacin was added to the culture medium. Moreover, we investigated whether or not additional cytostatic effect would be expected if indomethacin was used in combination with cis-platinum.
NSAID targets SIRT3 to trigger mitochondrial dysfunction and gastric cancer cell death

Subhashis Debsharma,Saikat Pramanik,Samik Bindu,Somnath Mazumder,Troyee Das,Uttam Pal,Debanjan Saha,Rudranil De,Shiladitya Nag,Chinmoy Banerjee,Nakul Chandra Maiti,Zhumur Ghosh,Uday Bandyopadhyay

DOI: https://doi.org/10.1016/j.isci.2024.109384

IF: 5.8

2024-04-01

iScience

Abstract:Gastric cancer (GC) is a deadly malignancy that demands effective therapeutic intervention capitalizing unique drug target/s. Here, we report that indomethacin, a cyclooxygenase non-selective non-steroidal anti-inflammatory drug, arrests GC cell growth by targeting mitochondrial deacetylase Sirtuin 3 (SIRT3). Interaction study revealed that indomethacin competitively inhibited SIRT3 by binding to nicotinamide adenine dinucleotide (NAD)-binding site. The Cancer Genome Atlas data meta-analysis indicated poor prognosis associated with high SIRT3 expression in GC. Further, transcriptome sequencing data of human gastric adenocarcinoma cells revealed that indomethacin treatment severely downregulated SIRT3. Indomethacin-induced SIRT3 downregulation augmented SOD2 and OGG1 acetylation, leading to mitochondrial redox dyshomeostasis, mtDNA damage, respiratory chain failure, bioenergetic crisis, mitochondrial fragmentation, and apoptosis via blocking the AMPK/PGC1α/SIRT3 axis. Indomethacin also downregulated SIRT3 regulators ERRα and PGC1α. Further, SIRT3 knockdown aggravated indomethacin-induced mitochondrial dysfunction as well as blocked cell-cycle progression to increase cell death. Thus, we reveal how indomethacin induces GC cell death by disrupting SIRT3 signaling.

multidisciplinary sciences
Multifunctional Indomethacin Conjugates for the Development of Nanosystems Targeting Cancer Treatment

Vaikunthavasan Thiruchenthooran,Marta Świtalska,Gabriela Maciejewska,Anna Palko-Łabuz,Lorena Bonilla-Vidal,Joanna Wietrzyk,Eliana Souto,Elena Sánchez-López,Anna Gliszczyńska

DOI: https://doi.org/10.2147/ijn.s477512

IF: 7.033

2024-11-28

International Journal of Nanomedicine

Abstract:Vaikunthavasan Thiruchenthooran, 1 Marta &Sacutewitalska, 2 Gabriela Maciejewska, 3, 4 Anna Palko-&Lstrokabuz, 5 Lorena Bonilla-Vidal, 6, 7 Joanna Wietrzyk, 2 Eliana B Souto, 8 Elena Sánchez-López, 6, 7, &ast Anna Gliszczy&nacuteska 1, &ast 1 Department of Food Chemistry and Biocatalysis, Wroc&lstrokaw University of Environmental and Life Sciences, Wroc&lstrokaw, Poland; 2 Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc&lstrokaw, Poland; 3 Central Laboratory of the Instrumental Analysis, Wroc&lstrokaw University of Technology, Wroc&lstrokaw, Poland; 4 Omics Research Center, Wroc&lstrokaw Medical University, Wroc&lstrokaw, Poland; 5 Department of Biophysics and Neuroscience, Wroc&lstrokaw Medical University, Wroc&lstrokaw, Poland; 6 Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, Barcelona, 08028, Spain; 7 Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, 08028, Spain; 8 UCD School of Chemical and Bioprocess Engineering, University College Dublin, Dublin, D04 V1W8, Ireland &astThese authors contributed equally to this work Correspondence: Anna Gliszczy&nacuteska; Elena Sánchez-López, Email ; Purpose: It is well known that the nonsteroidal anti-inflammatory drug (NSAID) indomethacin (IND) exhibits significant anticancer potential reported not only by in vitro and in vivo studies, but also in clinical trials. Despite promising results, IND is not widely used as an adjunctive agent in cancer therapy due to the occurrence of several gastrointestinal side effects, primarily after oral administration. Therefore, this study aimed to develop a nanosystem with reduced toxicity and risk of side effects for the delivery of IND for cancer treatment. Methods: IND was encapsulated in nanostructured lipid carriers (NLC) in the form of a phospholipid conjugate, where a covalent bond exists between the drug and phosphatidylcholine skeleton. For this purpose, seven new hybrid molecules were synthesized, and subsequently evaluated as anticancer agents in an in vitro model against selected cancer cell lines. Results: Biological studies demonstrated that the synthesized conjugates possessed excellent antiproliferative effects, exhibiting a 2.7-fold to even 100-fold higher activity against selected cancer cells, while remaining non-toxic to healthy cells. Based on biological studies and molecular calculations, heterosubstituted phosphatidylcholine containing IND and oleic acid (IND-OA-PC) in the sn -1 and sn -2 positions, respectively, was identified as the most potent molecule. Subsequently, IND-OA-PC was encapsulated in nanostructured lipid carriers (IND-OA-PC-NLC). The results revealed that IND-OA-PC-NLC has a spherical shape with an average diameter of 155 nm and a negatively charged surface (– 17.4 ± 0.49 mV). In this study, it was proven that the encapsulated conjugate of indomethacin with PC exhibits high activity against triple-negative (TNBC, Her2-, PR-, and ER-) breast cancer cells MDA-MB-468. While free IND was active at a concentration of 270.5 μM, in the form of the phospholipid conjugate (IND-OA-PC), it inhibited the growth of cancer cells at 67.5 μM and after conjugate encapsulation (IND-OA-PC-NLC) it was effective at only 10.3 μM. Conclusion: Our study revealed that the conjugation of NSAID with phosphatidylcholine and its combination with nanotechnology techniques create opportunities to repurpose well-known drugs from this group for new therapeutic applications. Keywords: indomethacin, phospholipid conjugates, long-chain fatty acids, nanostructured lipid carrier, nanoparticles, anticancer properties According to the report of the World Health Organization (WHO), cancer caused nearly 10 million deaths worldwide in 2020. 1 This staggering toll not only reflects the magnitude of human suffering, but also underscores the urgency to pursue effective interventions. Commonly used conventional therapies, such as chemotherapy and radiation, are often insufficient for tumor treatment. Moreover, neoadjuvant chemotherapy does not improve the patient's quality of life or guarantee overall survival compared to chemoradiotherapy. 2 Even adjuvant chemotherapy combinations do not provide the expected magnitude of survival benefit and often lead to more serious side effects than chemoradiotherapy alone. 3 Despite significant progress i -Abstract Truncated-

pharmacology & pharmacy,nanoscience & nanotechnology
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy

Nada S Aboelella,Caitlin Brandle,Ogacheko Okoko,Zhi-Chun Ding,Hongyan Xu,Gregory Gorman,Roni Bollag,Marco L Davila,Locke J Bryan,David H Munn,Gary A Piazza,Gang Zhou,Md Yeashin Gazi

DOI: https://doi.org/10.1136/jitc-2022-004938

IF: 12.469

2022-07-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Adoptive cell therapy (ACT) using genetically modified T cells has evolved into a promising treatment option for patients with cancer. However, even for the best-studied and clinically validated CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, many patients face the challenge of lack of response or occurrence of relapse. There is increasing need to improve the efficacy of ACT so that durable, curative outcomes can be achieved in a broad patient population. Methods Here, we investigated the impact of indomethacin (indo), a non-steroidal anti-inflammatory drug (NSAID), on the efficacy of ACT in multiple preclinical models. Mice with established B-cell lymphoma received various combinations of preconditioning chemotherapy, infusion of suboptimal dose of tumor-reactive T cells, and indo administration. Donor T cells used in the ACT models included CD4 + T cells expressing a tumor-specific T cell receptor (TCR) and T cells engineered to express CD19CAR. Mice were monitored for tumor growth and survival. The effects of indo on donor T cell phenotype and function were evaluated. The molecular mechanisms by which indo may influence the outcome of ACT were investigated. Results ACT coupled with indo administration led to improved tumor growth control and prolonged mouse survival. Indo did not affect the activation status and tumor infiltration of the donor T cells. Moreover, the beneficial effect of indo in ACT did not rely on its inhibitory effect on the immunosuppressive cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2) axis. Instead, indo-induced oxidative stress boosted the expression of death receptor 5 (DR5) in tumor cells, rendering them susceptible to donor T cells expressing TNF-related apoptosis-inducing ligand (TRAIL). Furthermore, the ACT-potentiating effect of indo was diminished against DR5-deficient tumors, but was amplified by donor T cells engineered to overexpress TRAIL. Conclusion Our results demonstrate that the pro-oxidative property of indo can be exploited to enhance death receptor signaling in cancer cells, providing rationale for combining indo with genetically modified T cells to intensify tumor cell killing through the TRAIL-DR5 axis. These findings implicate indo administration, and potentially similar use of other NSAIDs, as a readily applicable and cost-effective approach to augment the efficacy of ACT.

oncology,immunology
Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC)

Sruthi Sarvepalli,Vineela Parvathaneni,Gautam Chauhan,Snehal K Shukla,Vivek Gupta

DOI: https://doi.org/10.1007/s11095-022-03392-x

Abstract:Most lung cancer instances are non-small cell lung cancers (NSCLC). As stated by recent literature, cycloxygenase-2 (COX-2) is upregulated in lung adenocarcinomas. COX-2 relates to enhanced cell proliferation and reduced apoptosis; both of which are essential for an invasive tumor growth and metastasis. Thus, COX-2 inhibition forms an important checkpoint. Drug repurposing and nano drug delivery systems will enable the faster and more efficacious drug development. This study was designed to prepare, characterize, and establish superior effectiveness of indomethacin (IND), (a nonselective COX-2 inhibitor) as liposomes (IND-Lip). IND-Lip were made using thin film hydration method and physicochemical properties were characterized. Cell viability was performed on NSCLC cell lines (A549, H1299 and H460) Clonogenic, spheroidal, caspase and COX-2 assays were then carried out. IND-Lip were found to have optimum physicochemical properties. Based on IC50 value of 38.4 ± 4.9 µM, A549 cells were used for further assays. From clonogenic assay, % colonies were found to be 25.5 ± 9.5% at 200 µM of IND-Lip. IND-Lip performed significantly better in ex-vivo tumor reduction in 3D spheroid assay at 200 μM concentration, compared to plain IND by Day 15. Finally, a significant inhibition of COX-2 as well as induction of caspase in all IND treated groups was observed. It is of note that liposomes demonstrated a superior efficacy in all studies compared to the plain drug. IND through liposomal delivery system can be a potentially beneficial strategy for lung carcinoma. However, further clinical studies and in-vivo research are essential to comprehend the complete view of this approach.
Do we have to rethink serologic markers used to diagnose hepatitis B infection?

I. Roeckel

1989-11-01

Annals of clinical and laboratory science

Abstract:The recent addition of testing volunteer blood donors for antibody to hepatitis B core antigen (anti-HBc) has raised questions not apparent when such testing is applied to hepatitis B (HB) infected patients. The review of published studies, and our own, demonstrates that it is difficult to evaluate false positive results. Some patients appear to lose antibody to hepatitis B surface antigen (anti-HBs) but not antibody to hepatitis B core antigen (anti-HBc), thus raising the possibility of disease transmission. It is anticipated that additional investigation of individuals positive for anti-HBc only by response to hepatitis B vaccine permits clarification of their immune status and absence of infectivity.
Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism

Tracy Murray-Stewart,Christin L Hanigan,Patrick M Woster,Laurence J Marton,Robert A Casero Jr

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0418

Abstract:The treatment of specific tumor cell lines with poly- and oligoamine analogs results in a superinduction of polyamine catabolism that is associated with cytotoxicity; however, other tumor cells show resistance to analog treatment. Recent data indicate that some of these analogs also have direct epigenetic effects. We, therefore, sought to determine the effects of combining specific analogs with an epigenetic targeting agent in phenotypically resistant human lung cancer cell lines. We show that the histone deacetylase inhibitor MS-275, when combined with (N(1), N(11))-bisethylnorspermine (BENSpm) or (N(1), N(12))-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride (PG-11047), synergistically induces the polyamine catabolic enzyme spermidine/spermine N(1)-acetyltransferase (SSAT), a major determinant of sensitivity to the antitumor analogs. Evidence indicates that the mechanism of this synergy includes reactivation of miR-200a, which targets and destabilizes kelch-like ECH-associated protein 1 (KEAP1) mRNA, resulting in the translocation and binding of nuclear factor (erythroid-derived 2)-like 2 (NRF2) to the polyamine-responsive element of the SSAT promoter. This transcriptional stimulation, combined with positive regulation of SSAT mRNA and protein by the analogs, results in decreased intracellular concentrations of natural polyamines and growth inhibition. The finding that an epigenetic targeting agent is capable of inducing a rate-limiting step in polyamine catabolism to overcome resistance to the antitumor analogs represents a completely novel chemotherapeutic approach. In addition, this is the first demonstration of miRNA-mediated regulation of the polyamine catabolic pathway. Furthermore, the individual agents used in this study have been investigated clinically; therefore, translation of these combinations into the clinical setting holds promise.
On the Bayesian Estimation of a Closed Population Size in the Presence of Heterogeneity and Model Uncertainty

Ruth King,S. Brooks

DOI: https://doi.org/10.1111/j.1541-0420.2007.00938.x

IF: 1.701

2007-11-28

Biometrics

Abstract:Summary We consider the estimation of the size of a closed population, often of interest for wild animal populations, using a capture–recapture study. The estimate of the total population size can be very sensitive to the choice of model used to fit to the data. We consider a Bayesian approach, in which we consider all eight plausible models initially described by Otis et al. (1978, Wildlife Monographs62, 1–135) within a single framework, including models containing an individual heterogeneity component. We show how we are able to obtain a model‐averaged estimate of the total population, incorporating both parameter and model uncertainty. To illustrate the methodology we initially perform a simulation study and analyze two datasets where the population size is known, before considering a real example relating to a population of dolphins off northeast Scotland.
Effects of Indomethacin on the Growth and Metastasis of Hepatocellular Carcinoma

ZHOU Jian-wei,TANG Zhao-you,REN Zheng-gang,LI Tao,YUE Fan,WANG Wen-quan,ZHOU Yun,LUO Zhi-fen

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2011.05.021

2011-01-01

Abstract:Objective To study the effects of indomethacin on proliferation and invasion of hepatocellular carcinoma (HCC) cell line MHCC97L with metastatic potential and the effect of indomethacin on the growth and metastasis of HCC. Methods (1) In vitro; Proliferation, Transwell invasion assay, cell motility assay, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) protein activity were evaluated after cells were treated with 0. 2 mmol/L indomethacin. (2)In vivo: Mice bearing xenografts in the liver were randomly divided into control and indomethacin groups. At the end of sixth week, the mice were killed and tumor volume, inhibitory rate, immunohistochemistry assay (IHA) and metastasis were evaluated. Results (1)In vitro; 0. 2 mmol/L indomethacin could inhibit the proliferation of MHCC97L cells markedly (P ＜0. 01). The average amount of invading cells per field in cell invasion assay and motility assay was 2. 2 ± 1. 3 and 4.4 ± 1. 1 respectively in indomethacin group, significantly less than in control group ( 11. 4 ± 1. 9 and 12. 8 ± 1. 8 respectively, P ＜0. 01). The expression of VEGF and MMP-2 in cells treated with indomethacin was significantly lower than in control group (P ＜0. 01). (2)In vivo; Tumor volume, incidence and number of lung metastases in control and indomethacin groups were (1700 ±422) mm3 and (1170 ± 585) mm3 (P ＜ 0. 05), 75% and 50% ( P ＞ 0.05), 2. 92 ± 2. 07 and 1.33 ±1.56 (P＜0. 05) , respectively. Inhibition rate in indomethacin group was 31.2%. IHA showed that the expression of VEGF, MMP-2, and cyclooxygenase-2 ( COX-2) was down-regulated in indomethacin group (P ＜0.01). Conclusion Indomethacin could inhibit the growth and metastasis of HCC, which was in part mediated by down-regulation of VEGF and MMP-2.
The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity

Yi-Fei Xuan,Shan Lu,Ying-Jie Ou,Xu-Bin Bao,Xia-Juan Huan,Shan-Shan Song,Ze-Hong Miao,Ying-Qing Wang

DOI: https://doi.org/10.1016/j.bbrc.2024.150011

2024-07-05

Abstract:Methionine adenosyltransferase 2 A (MAT2A) mediates the synthesis of methyl donor S-Adenosylmethionine (SAM), providing raw materials for methylation reactions in cells. MAT2A inhibitors are currently used for the treatment of tumors with methylthioadenosine phosphorylase (MTAP) deficiency in clinical research. Methyltransferase like 3 (METTL3) catalyzes N6-methyladenosine (m6A) modification of mRNA in mammalian cells using SAM as the substrate which has been shown to affect the tumorigenesis of non-small cell lung cancer (NSCLC) from multiple perspectives. MAT2A-induced SAM depletion may have the potential to inhibit the methyl transfer function of METTL3. Therefore, in order to expand the applicability of inhibitors, improve anti-tumor effects and reduce toxicity, the combinational effect of MAT2A inhibitor AG-270 and METTL3 inhibitor STM2457 was evaluated in NSCLC. The results showed that this combination induced cell apoptosis rather than cell cycle arrest, which was non-tissue-specific and was independent of MTAP expression status, resulting in a significant synergistic anti-tumor effect. We further elucidated that the combination-induced enhanced apoptosis was associated with the decreased m6A level, leading to downregulation of PI3K/AKT protein, ultimately activating the apoptosis-related proteins. Unexpectedly, although combination therapy resulted in metabolic recombination, no significant change in methionine metabolic metabolites was found. More importantly, the combination also exerted synergistic effects in vivo. In summary, the combination of MAT2A inhibitor and METTL3 inhibitor showed synergistic effects both in vivo and in vitro, which laid a theoretical foundation for expanding the clinical application research of the two types of drugs.
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment

Cara C. Schafer,Yong Wang,Kenneth P. Hough,Anandi Sawant,Stefan C. Grant,Victor J. Thannickal,Jaroslaw Zmijewski,Selvarangan Ponnazhagan,Jessy S. Deshane

DOI: https://doi.org/10.18632/oncotarget.12249

2016-09-26

Oncotarget

Abstract:Indoleamine 2,3-dioxygenase (IDO) has been implicated in immune evasion by tumors. Upregulation of this tryptophan (Trp)-catabolizing enzyme, in tumor cells and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME), leads to Trp depletion that impairs cytotoxic T cell responses and survival; however, exact mechanisms remain incompletely understood. We previously reported that a combination therapy of gemcitabine and a superoxide dismutase mimetic promotes anti-tumor immunity in a mouse model of lung cancer by inhibiting MDSCs, enhancing polyfunctional response of CD8+ memory T cells, and extending survival. Here, we show that combination therapy targets IDO signaling, specifically in MDSCs, tumor cells, and CD8+ T cells infiltrating the TME. Deficiency of IDO caused significant reduction in tumor burden, tumor-infiltrating MDSCs, GM-CSF, MDSC survival and infiltration of programmed death receptor-1 (PD-1)-expressing CD8+ T cells compared to controls. IDO-/- MDSCs downregulated nutrient-sensing AMP-activated protein kinase (AMPK) activity, but IDO-/- CD8+ T cells showed AMPK activation associated with enhanced effector function. Our studies provide proof-of-concept for the efficacy of this combination therapy in inhibiting IDO and T cell exhaustion in a syngeneic model of lung cancer and provide mechanistic insights for IDO-dependent metabolic reprogramming of MDSCs that reduces T cell exhaustion and regulates anti-tumor immunity.
Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets

Chinthalapally V Rao,Bandaru S Reddy,Vernon E Steele,C-X Wang,Xiaoping Liu,Nengtai Ouyang,Jagan M R Patlolla,Barbara Simi,Levy Kopelovich,Basil Rigas

DOI: https://doi.org/10.1158/1535-7163.MCT-06-0061

Abstract:Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAID) are promising chemoprevention agents; unlike conventional NSAIDs, they seem free of appreciable adverse effects, while they retain beneficial activities of their parent compounds. Their effect on colon carcinogenesis using carcinoma formation as an end point is unknown. We assessed the chemopreventive properties of NO-indomethacin (NCX 530) and NO-aspirin (NCX 4016) against azoxymethane-induced colon cancer. Seven-week-old male F344 rats were fed control diet, and 1 week later, rats received two weekly s.c. injections of azoxymethane (15 mg/kg body weight). Two weeks after azoxymethane treatment, rats (48 per group) were fed experimental diets containing NO-indomethacin (0, 40, or 80 ppm), or NO-aspirin (1,500 or 3,000 ppm), representing 40% and 80% of the maximum tolerated dose. All rats were killed 48 weeks after azoxymethane treatment and assessed for colon tumor efficacy and molecular changes in colonic tumors and normally appearing colonic mucosa of different dietary groups. Our results suggest that NO-indomethacin at 40 and 80 ppm and NO-aspirin at 3,000 ppm significantly suppressed both tumor incidence (P < 0.01) and multiplicity (P < 0.001). The degree of inhibition was more pronounced with NO-indomethacin at both dose levels (72% and 76% inhibition) than with NO-aspirin (43% and 67%). NO-indomethacin at 40 and 80 ppm and NO-aspirin at 3,000 ppm significantly inhibited the colon tumors' (P < 0.01 to P < 0.001) total cyclooxygenase (COX), including COX-2 activity (52-75% inhibition) and formation of prostaglandin E2 (PGE2), PGF2alpha, and 6-keto-PGF1alpha, and TxB2 from arachidonic acid (53-77% inhibition). Nitric oxide synthase 2 (NOS-2) activity and beta-catenin expression were suppressed in animals given NO-NSAID. In colonic crypts and tumors of animals fed these two NO-NSAIDs, there was a significant decrease in proliferating cell nuclear antigen labeling when compared with animals fed the control diet. The results of this study provide strong evidence that NO-NSAIDs possess strong inhibitory effect against colon carcinogenesis; their effect is associated with suppression of COX and NOS-2 activities and beta-catenin levels in colon tumors. These results pave the way for the rational design of human clinical trials.
LDH-Indomethacin Nanoparticles Antitumoral Action: A Possible Coadjuvant Drug for Cancer Therapy

Kelly Costa Alves,Carlos Emmerson Ferreira da Costa,Cláudio Márcio Rocha Remédios,Danielle Queiroz Calcagno,Marcelo de Oliveira Lima,José Rogério A Silva,Cláudio Nahum Alves

DOI: https://doi.org/10.3390/molecules29143353

IF: 4.6

2024-07-17

Molecules

Abstract:Indomethacin (INDO) has a mechanism of action based on inhibiting fatty acids cyclooxygenase activity within the inflammation process. The action mechanism could be correlated with possible anticancer activity, but its high toxicity in normal tissues has made therapy difficult. By the coprecipitation method, the drug carried in a layered double hydroxides (LDH) hybrid matrix would reduce its undesired effects by promoting chemotherapeutic redirection. Therefore, different samples containing INDO intercalated in LDH were synthesized at temperatures of 50, 70, and 90 °C and synthesis times of 8, 16, 24, and 48 h, seeking the best structural organization. X-ray diffraction (XRD), vibrational Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), spectrophotometric analysis in UV-VIS, and differential thermogravimetric analysis (TGA/DTA) were used for characterization. Our results indicate that higher temperatures and longer synthesis time through coprecipitation reduce the possibility of INDO intercalation. However, it was possible to establish a time of 16 h and a temperature of 50 °C as the best conditions for intercalation. In vitro results confirmed the cell viability potential and anticancer activity in the LDH-INDO sample (16 h and 50 °C) for gastric cancer (AGP01, ACP02, and ACP03), breast cancer (MDA-MB-231 and MCF-7), melanoma (SK-MEL-19), lung fibroblast (MRC-5), and non-neoplastic gastric tissue (MN01) by MTT assay. Cell proliferation was inhibited, demonstrating higher and lower toxicity against MDA-MB-231 and SK-MEL-19. Thus, a clinical redirection of INDO is suggested as an integral and adjunctive anticancer medication in chemotherapy treatment.
Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma

Fangfang Liu,Qiong Wu,Wei Han,Kyle Laster,Yamei Hu,Fayang Ma,Hanyong Chen,Xueli Tian,Yan Qiao,Hui Liu,Dong Joon Kim,Zigang Dong,Kangdong Liu

DOI: https://doi.org/10.1002/ctm2.548

IF: 8.554

2021-10-01

Clinical and Translational Medicine

Abstract:RATIONALE: A high risk of post-operative recurrence contributes to the poor prognosis and low survival rate of oesophageal squamous cell carcinoma (ESCC) patients. Increasing experimental evidence suggests that integrin adhesion receptors, in particular integrin αv (ITGAV), are important for cancer cell survival, proliferation and migration. Therefore, targeting ITGAV may be a rational approach for preventing ESCC recurrence.MATERIALS AND METHODS: Protein levels of ITGAV were determined in human ESCC tumour tissues using immunohistochemistry. MTT, propidium iodide staining, and annexin V staining were utilized to investigate cell viability, cell cycle progression, and induction of apoptosis, respectively. Computational docking was performed with the Schrödinger Suite software to visualize the interaction between indomethacin and ITGAV. Cell-derived xenograft mouse models, patient-derived xenograft (PDX) mouse models, and a humanized mouse model were employed for in vivo studies.RESULTS: ITGAV was upregulated in human ESCC tumour tissues and increased ITGAV protein levels were associated with poor prognosis. ITGAV silencing or knockout suppressed ESCC cell growth and metastatic potential. Interestingly, we identified that indomethacin can bind to ITGAV and enhance synovial apoptosis inhibitor 1 (SYVN1)-mediated degradation of ITGAV. Integrin β3, one of the β subunits of ITGAV, was also decreased at the protein level in the indomethacin treatment group. Importantly, indomethacin treatment suppressed ESCC tumour growth and prevented recurrence in a PDX mouse model. Moreover, indomethacin inhibited the activation of cytokine TGFβ, reduced SMAD2/3 phosphorylation, and increased anti-tumour immune responses in a humanized mouse model.CONCLUSION: ITGAV is a promising therapeutic target for ESCC. Indomethacin can attenuate ESCC growth through binding to ITGAV, promoting SYVN1-mediated ubiquitination of ITGAV, and potentiating cytotoxic CD8<sup>+</sup> T cell responses.

oncology,medicine, research & experimental
Oral Administration of Swine Gastric Mucin Alters Levels of Serum and Urine Nitric Oxide, and Lipid Metabolism in Mice

A. Khedara,M. Miwa

DOI: https://doi.org/10.1271/bbb.66.853

2002-01-01

Abstract:Mice were fed with swine gastric mucin in a basal diet for 5 weeks. In 5 week-old mice, a 2% mucin diet significantly decreased nitric oxide levels of serum and liver. Reduction of serum total cholesterol and triglyceride and increase of HDL-cholesterol level were also significant with the mucin diet. In 14 month-old mice, the mucin diet was less effective.
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line

Ellen Ackerstaff,Barjor Gimi,Dmitri Artemov,Zaver M Bhujwalla

DOI: https://doi.org/10.1593/neo.06673

IF: 6.218

Neoplasia

Abstract:Hostile physiological environments such as hypoxia and acidic extracellular pH, which exist in solid tumors, may promote invasion and metastasis through inflammatory responses and formation of eicosanoids. Here, we have investigated the effects of the anti-inflammatory agent indomethacin on the invasion and metabolism of the human breast cancer cell line MDA-MB-435 in Dulbecco's Modified Eagles (DME)-based or Roswell Park Memorial Institute (RPMI)-based cell medium, using a magnetic resonance-compatible invasion assay. Indomethacin treatment significantly reduced the invasion of MDA-MB-435 cells independent of the culture and perfusion conditions examined. Significant changes were detected in levels of intracellular choline phospholipid metabolites and in triglyceride (TG) concentrations of these cells, depending on indomethacin treatment and basal cell medium used. Additionally, genetic profiling of breast cancer cells, grown and treated with low-dose indomethacin in cell culture using an RPMI-based medium, revealed the upregulation of several genes implicating cyclooxygenase-independent targets of indomethacin. These data confirm the ability of an anti-inflammatory agent to reduce breast cancer invasion and demonstrate, depending on cell culture and perfusion conditions, that the indomethacin-induced decrease in invasion is associated with changes in choline phospholipid metabolism, TG metabolism, and gene expression.

Paget's carcinoma of the breast.

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

S-adenosylmethionine Inhibits Non-Small Cell Lung Cancer and Enhances Chemosensitivity by Targeting the P62/NF-κB Axis and Regulating Autophagy and Oxidative Stress

Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.

Nicotinamide N-methyltransferase Enhances the Capacity of Tumorigenesis Associated with the Promotion of Cell Cycle Progression in Human Colorectal Cancer Cells.

NSAID Indomethacin Enhanced Cytostatic Effect of Cis-Platinum of the Proliferation of Prostaglandin Producing and Non-Producing Cancers in Cell Line

NSAID targets SIRT3 to trigger mitochondrial dysfunction and gastric cancer cell death

Multifunctional Indomethacin Conjugates for the Development of Nanosystems Targeting Cancer Treatment

Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy

Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC)

Do we have to rethink serologic markers used to diagnose hepatitis B infection?

Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism

On the Bayesian Estimation of a Closed Population Size in the Presence of Heterogeneity and Model Uncertainty

Effects of Indomethacin on the Growth and Metastasis of Hepatocellular Carcinoma

The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment

Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets

LDH-Indomethacin Nanoparticles Antitumoral Action: A Possible Coadjuvant Drug for Cancer Therapy

Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma

Oral Administration of Swine Gastric Mucin Alters Levels of Serum and Urine Nitric Oxide, and Lipid Metabolism in Mice

Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line